Exabis Library
Welcome to the e-CCO Library!
P647: Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P647: Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P647: Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P648: Anti-TNF-α therapy, use of corticosteroids, and colectomy among paediatric and adolescent patients with ulcerative colitis: a nationwide study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P648: Clinical feasibility of dried blood sampling for infliximab in IBD patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P648: Effectiveness of Biologic Therapies in Decreasing Risk of Hospitalization and Surgery, Maintaining Steroid Free Remission and Achieving Mucosal Healing in Inflammatory Bowel Disease; Real World Data.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P648: Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P648: Prevalence and Impact of Alcohol Consumption and Cannabis Use on Inflammatory Bowel Diseases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P648: The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P649 Dietary habits in patients with inactive Crohn’s disease: Results of a controlled study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P649: Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P649: Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P649: Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P649: Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P649: The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases – A Danish prospective population-based cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P649: Ulcerative Colitis Narrative Japanese survey: Identifying gaps between patient and healthcare professional perspectives on communication and disease management to optimise patient care
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P650 Outcomes of endoscopic balloon dilation for luminal strictures in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P650: A trend to higher adoption of mesalazine suppository use for UC patients in 15 European countries
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P650: Combination therapy for perianal fistulising Crohn’s disease in biological era: What is the optimal time for surgical intervention?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM